Theoharis Theoharides: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(refs errors)
Line 5: Line 5:


==Notable studies==
==Notable studies==
Dr. Theoharides has published over 270 research papers and 2 textbooks of Pharmacology.<ref>{{Cite news|url=http://www.brain-gate.org/en/component/k2/item/253-theocharides|title=President Theoharis C. Theoharides, MS, PhD, MD, FAAAAI|last=|first=|date=|work=Brain~Gate.org|access-date=2018-08-16|archive-url=|archive-date=|dead-url=|language=}}</ref>
Dr. Theoharides has published over 270 research papers and 2 textbooks of Pharmacology.<ref>{{Cite web|url=https://www.brain-gate.org/en/component/k2/item/253-theocharides|title=President Theoharis C. Theoharides, MS, PhD, MD, FAAAAI|last=|first=|authorlink=|last2=|first2=|authorlink2=|date=|website=Brain-Gate.org|language=en-gb|archive-url=|archive-date=|url-status=|access-date=2021-03-18}}</ref>
* 2014, Isoflavones inhibit poly(I:C)-induced serum, brain, and skin inflammatory mediators - relevance to [[chronic fatigue syndrome]]<ref>{{Cite journal|last=Vasiadi|first=Magdalini|last2=Newman|first2=Jennifer|last3=Theoharides|first3=Theoharis C|author-link3=Theoharis Theoharides|date=31 Oct 2014|title=Isoflavones inhibit poly(I:C)-induced serum, brain, and skin inflammatory mediators - relevance to chronic fatigue syndrome|url=http://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-014-0168-5|journal=Journal of Neuroinflammation|language=En|volume=11|issue=1|pages=|doi=10.1186/s12974-014-0168-5|issn=1742-2094|pmc=|pmid=25359293|via=}}</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236420/ (Full text)]
* 2014, Isoflavones inhibit poly(I:C)-induced serum, brain, and skin inflammatory mediators - relevance to [[chronic fatigue syndrome]]<ref>{{Cite journal|last=Vasiadi|first=Magdalini|last2=Newman|first2=Jennifer|last3=Theoharides|first3=Theoharis C|author-link3=|date=31 Oct 2014|title=Isoflavones inhibit poly(I:C)-induced serum, brain, and skin inflammatory mediators - relevance to chronic fatigue syndrome|url=http://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-014-0168-5|journal=Journal of Neuroinflammation|language=En|volume=11|issue=1|pages=|doi=10.1186/s12974-014-0168-5|issn=1742-2094|pmc=|pmid=25359293|via=|quote=|last4=|first4=|last5=|first5=|last6=|first6=|last7=|first7=|last8=|first8=|author-link=|author-link2=|access-date=|author-link4=|author-link5=|author-link6=}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236420/ (Full text)]


* 2018, [[Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: History, Diagnostic Criteria, and Prevalence|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome]] - metabolic disease or disturbed homeostasis?<ref>{{Cite journal|last=Hatziagelaki|first=Erifili|last2=Adamaki|first2=Maria|last3=Tsilioni|first3=Irene|last4=Dimitriadis|first4=George|last5=Theoharides|first5=Theoharis C.|author-link5=Theoharis Theoharides|date=2018-01-01|title=Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Metabolic Disease or Disturbed Homeostasis?|url=http://jpet.aspetjournals.org/content/early/2018/08/03/jpet.118.250845|journal=Journal of Pharmacology and Experimental Therapeutics|language=en|volume=|pages=jpet.118.250845|doi=10.1124/jpet.118.250845|issn=0022-3565|pmid=30076265|via=}}</ref> [http://jpet.aspetjournals.org/content/jpet/early/2018/08/03/jpet.118.250845.full.pdf (Full Text)]
* 2018, [[Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: History, Diagnostic Criteria, and Prevalence|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome]] - metabolic disease or disturbed homeostasis?<ref>{{Cite journal|last=Hatziagelaki|first=Erifili|last2=Adamaki|first2=Maria|last3=Tsilioni|first3=Irene|last4=Dimitriadis|first4=George|last5=Theoharides|first5=Theoharis C.|author-link5=|date=2018-01-01|title=Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Metabolic Disease or Disturbed Homeostasis?|url=http://jpet.aspetjournals.org/content/early/2018/08/03/jpet.118.250845|journal=Journal of Pharmacology and Experimental Therapeutics|language=en|volume=|pages=jpet.118.250845|doi=10.1124/jpet.118.250845|issn=0022-3565|pmid=30076265|via=|issue=|pmc=|quote=|last6=|first6=|last7=|first7=|last8=|first8=|author-link=|author-link2=|access-date=|author-link3=|author-link4=|author-link6=}}</ref> - [http://jpet.aspetjournals.org/content/jpet/early/2018/08/03/jpet.118.250845.full.pdf (Full Text)]
* 2018, Tetramethoxyluteolin for the treatment of neurodegenerative diseases<ref>{{Cite journal|last=Theoharides|first=Theoharis C.|author-link=Theoharis Theoharides|last2=Tsilioni|first2=Irene|author-link2=|author-link3=|author-link4=|author-link5=|date=2018-11-19|title=Tetramethoxyluteolin for the treatment of neurodegenerative diseases,|url=http://www.eurekaselect.com/167495/article|journal=Current Topics in Medicinal Chemistry|language=en|volume=18|issue=|pages=|doi=10.2174/1568026617666181119154247|issn=1568-0266|quote=|via=}}</ref>
* 2018, Tetramethoxyluteolin for the treatment of neurodegenerative diseases<ref>{{Cite journal|last=Theoharides|first=Theoharis C.|author-link=|last2=Tsilioni|first2=Irene|author-link2=|author-link3=|author-link4=|author-link5=|date=2018-11-19|title=Tetramethoxyluteolin for the treatment of neurodegenerative diseases,|url=http://www.eurekaselect.com/167495/article|journal=Current Topics in Medicinal Chemistry|language=en|volume=18|issue=|pages=|doi=10.2174/1568026617666181119154247|issn=1568-0266|quote=|via=|pmc=|pmid=|last3=|first3=|last4=|first4=|last5=|first5=|last6=|first6=|last7=|first7=|last8=|first8=|access-date=|author-link6=}}</ref>


==Talks and interviews==
==Talks and interviews==
*2015, [https://www.youtube.com/watch?v=92nrFwcNSwc Dr. T. C. Theoharides presents “Mast Cell Disorders”]<ref>{{Cite web|url=https://www.youtube.com/watch?v=92nrFwcNSwc|title=Dr. T. C. Theoharides presents “Mast Cell Disorders”|last=|first=|date=Jun 3, 2015|website=YouTube|publisher=EDS Awareness|archive-url=|archive-date=|dead-url=|access-date=}}</ref>
*2015, [https://www.youtube.com/watch?v=92nrFwcNSwc Dr. T. C. Theoharides presents “Mast Cell Disorders”]<ref>{{Cite web|url=https://www.youtube.com/watch?v=92nrFwcNSwc|title=Dr. T. C. Theoharides presents “Mast Cell Disorders"|last=|first=|authorlink=|last2=|first2=|authorlink2=|date=|website=YouTube|archive-url=|archive-date=|url-status=|access-date=2021-03-18}}</ref>
*1 Jun 2018, Speaker at the 13th Invest in ME International ME Conference''; Speech title: Anne Örtegren Memorial  Lecture - Mast Cells and ME''<ref>{{Cite web|url=http://www.investinme.org/IIMEC13-13-13-Agenda.shtml|title=Invest in ME Research - IIMEC13 Invest in ME Research ME Conference 2018|website=www.investinme.org|access-date=2018-08-16}}</ref> ''-'' [https://www.youtube.com/watch?v=HNNPsZlDTEQ (Video)]   
*1 Jun 2018, Speaker at the 13th Invest in ME International ME Conference''; Speech title: Anne Örtegren Memorial  Lecture - Mast Cells and ME''<ref>{{Cite web|url=http://www.investinme.org/IIMEC13-13-13-Agenda.shtml|title=Invest in ME Research - IIMEC13 Invest in ME Research ME Conference 2018|website=www.investinme.org|access-date=2018-08-16}}</ref> ''-'' [https://www.youtube.com/watch?v=HNNPsZlDTEQ (Video)]   


Line 20: Line 20:


==See also==
==See also==
*[[Eirini Tsilioni]]
*[[Mast cell]]
*[[Mast cell]]
*[[Mast cell activation disorder]]
*[[Mast cell activation disorder]]


==Learn more==
==Learn more==
*[http://mastcellmaster.com/cv/TCT-full-cv-10-3-15R.pdf Curriculum Vitae]<ref>{{Cite web|url=http://mastcellmaster.com/cv/TCT-full-cv-10-3-15R.pdf|title=Curriculum Vitae|last=Theoharides|first=Theoharis C.|date=Oct 3, 2015|website=mastcellmaster.com|archive-url=|archive-date=|dead-url=|access-date=}}</ref>
*[http://mastcellmaster.com/cv/TCT-full-cv-10-3-15R.pdf Curriculum Vitae]<ref>{{Cite web|url=http://mastcellmaster.com/cv/TCT-full-cv-10-3-15R.pdf|title=Curriculum Vitae - Theoharis C. Theoharides|last=|first=|authorlink=|last2=|first2=|authorlink2=|date=|website=mastcellmaster.com|archive-url=|archive-date=|url-status=|access-date=2021-03-18}}</ref>
*[http://www.mastcellmaster.com/ Molecular Immunopharmacology and Drug Discovery Website]<ref>{{Cite web|url=http://www.mastcellmaster.com/|title=Dr T C Theoharides, MD  Ph.D., - Mast Cells, Autism, Inflammation|website=www.mastcellmaster.com|language=en|access-date=2018-08-16}}</ref>
*[http://www.mastcellmaster.com/ Molecular Immunopharmacology and Drug Discovery Website]<ref>{{Cite web|url=http://www.mastcellmaster.com/|title=Dr T C Theoharides, MD  Ph.D., - Mast Cells, Autism, Inflammation|website=www.mastcellmaster.com|language=en|access-date=2018-08-16}}</ref>
*[https://sackler.tufts.edu/facultyResearch/faculty/theoharides-theoharis Theoharis Theoharides Lab]<ref>{{Cite news|url=https://sackler.tufts.edu/facultyResearch/faculty/theoharides-theoharis|title=Theoharis Theoharides|date=2018-04-09|work=Sackler School of Graduate Biomedical Sciences|access-date=2018-08-16|language=en}}</ref>
*[https://sackler.tufts.edu/facultyResearch/faculty/theoharides-theoharis Theoharis Theoharides Lab]<ref>{{Cite news|url=https://sackler.tufts.edu/facultyResearch/faculty/theoharides-theoharis|title=Theoharis Theoharides|date=2018-04-09|work=Sackler School of Graduate Biomedical Sciences|access-date=2018-08-16|language=en}}</ref>

Revision as of 18:38, March 18, 2021

Theoharis Theoharides.png

Theoharis C. Theoharides, MS, MPhil, PhD, MD, is a Professor of Pharmacology and Internal Medicine and the Director of the Molecular Immunopharmacology and Drug Discovery Laboratory at Tufts University School of Medicine, Boston, Massachusetts, US. His lab, the Theoharis Theoharides Lab, at Sackler School of Graduate Biomedical Sciences, investigates the mechanism of selective secretion of cytokines and other pro-inflammatory molecules from mast cells.[1]

Dr. Theoharides's special interests include mechanisms of inflammation, neuroimmunoendocrine disorders, mast cell activation disorders, autism, and Ehlers-Danlos syndrome.

Notable studies[edit | edit source]

Dr. Theoharides has published over 270 research papers and 2 textbooks of Pharmacology.[2]

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "Theoharis Theoharides". Sackler School of Graduate Biomedical Sciences. April 9, 2018. Retrieved August 16, 2018.
  2. "President Theoharis C. Theoharides, MS, PhD, MD, FAAAAI". Brain-Gate.org. Retrieved March 18, 2021.
  3. Vasiadi, Magdalini; Newman, Jennifer; Theoharides, Theoharis C (October 31, 2014). "Isoflavones inhibit poly(I:C)-induced serum, brain, and skin inflammatory mediators - relevance to chronic fatigue syndrome". Journal of Neuroinflammation. 11 (1). doi:10.1186/s12974-014-0168-5. ISSN 1742-2094. PMID 25359293.
  4. Hatziagelaki, Erifili; Adamaki, Maria; Tsilioni, Irene; Dimitriadis, George; Theoharides, Theoharis C. (January 1, 2018). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Metabolic Disease or Disturbed Homeostasis?". Journal of Pharmacology and Experimental Therapeutics: jpet.118.250845. doi:10.1124/jpet.118.250845. ISSN 0022-3565. PMID 30076265.
  5. Theoharides, Theoharis C.; Tsilioni, Irene (November 19, 2018). "Tetramethoxyluteolin for the treatment of neurodegenerative diseases,". Current Topics in Medicinal Chemistry. 18. doi:10.2174/1568026617666181119154247. ISSN 1568-0266.
  6. "Dr. T. C. Theoharides presents "Mast Cell Disorders"". YouTube. Retrieved March 18, 2021.
  7. "Invest in ME Research - IIMEC13 Invest in ME Research ME Conference 2018". www.investinme.org. Retrieved August 16, 2018.
  8. "Curriculum Vitae - Theoharis C. Theoharides" (PDF). mastcellmaster.com. Retrieved March 18, 2021.
  9. "Dr T C Theoharides, MD Ph.D., - Mast Cells, Autism, Inflammation". www.mastcellmaster.com. Retrieved August 16, 2018.
  10. "Theoharis Theoharides". Sackler School of Graduate Biomedical Sciences. April 9, 2018. Retrieved August 16, 2018.